Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company whose news flow centers on the development of immunotherapy medicines based on halogenated xanthenes, particularly its lead molecule rose bengal sodium. As an OTCQB-traded company, Provectus regularly issues updates on preclinical and clinical research, investor events, and corporate initiatives that shape the outlook for its investigational programs.
News about Provectus often highlights progress with PV-10, the company’s rose bengal sodium-based investigational cancer immunotherapy. Recent announcements have covered preclinical studies in head and neck squamous cell carcinoma, orthotopic bladder cancer models using oral and intravesical PV-10, and mechanistic work showing activation of the STING immune pathway and enhanced T-cell responses in vaccine settings. These items provide insight into how the company is exploring PV-10 across oncology and immunology applications.
Investors and researchers following PVCT can also expect updates on wound healing and dermatology research, such as non-clinical data on full-thickness cutaneous wounds, as well as ophthalmology developments through the VisiRose founded entity focused on rose bengal sodium-based eye therapies. Additional news items include announcements of annual stockholder meetings, investor webinars, and conference calls, which offer company updates and access to management presentations.
This PVCT news page aggregates these disclosures in one place, making it easier to review Provectus’s latest scientific publications, collaboration highlights, and corporate communications. For anyone tracking the evolution of its rose bengal sodium platform across oncology, dermatology, ophthalmology, infectious diseases, and tissue repair research, this feed provides an organized view of the company’s reported milestones and ongoing activities.
Provectus (OTCQB: PVCT) has updated its research on the systemic administration of PV-10, an investigational immunotherapy, focusing on hematology, oncology, and virology. The Company announced new patent applications published by the USPTO, showcasing in vivo data from studies on leukemia and solid tumors that demonstrated increased survival rates in mice. Provectus plans to publish findings from these studies in peer-reviewed journals in 2022. The Company continues to seek patent protection globally and emphasizes the significance of its immune system research.
Provectus (OTCQB: PVCT) announced the presentation of data from historical clinical trials and ongoing studies of its cancer immunotherapy PV-10 at the upcoming SMR 2021 Congress, scheduled for October 28-31. The accepted abstracts will discuss PV-10's efficacy in Stage III melanoma and its combination with anti-PD-1 therapy for checkpoint-refractory patients. PV-10 has been administered to over 450 patients, showing potential for inducing immune responses against solid tumors. The company is focused on developing immunotherapy treatments for various cancers.
Provectus (OTCQB: PVCT) presented data from an ongoing clinical trial of PV-10 for treating metastatic neuroendocrine tumors at the ESMO Congress (Sept 16-21, 2021). The trial involved 12 patients, showing an objective response rate of 42% and a disease control rate of 83%. Median progression-free survival was 9.2 months, with overall survival at 22.5 months. Notable adverse effects included injection site pain in 75% of patients. The CEO expressed optimism regarding PV-10’s potential in refractory cases and future Phase 2 testing. Data collection is expected to finalize in Q4 2021.
Provectus (OTCQB: PVCT) announced the presentation of data from an ongoing clinical trial of PV-10, an investigational cancer immunotherapy for neuroendocrine tumors (NET) metastatic to the liver, at the European Society for Medical Oncology Congress from September 16-21, 2021. The abstract, titled “Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms” (#4354), highlights PV-10's potential in treating this challenging cancer type.
Provectus (PVCT) announced promising preclinical data on its investigational cancer treatment, PV-10, presented at the ASCO 2021 Annual Meeting. The study focused on oral delivery of PV-10 for adult solid tumors, demonstrating autophagic cell death across various cancer cell lines, including breast, colorectal, head and neck, and testicular cancers. Key findings revealed that testicular cancer cells showed the highest sensitivity to PV-10. The research led by Aru Narendran, MD, PhD, highlights the potential for PV-10 to selectively target certain cancers while maintaining a wide therapeutic window.
Provectus (OTCQB: PVCT) reported promising preliminary data from its Phase 1 clinical trial of PV-10 for treating neuroendocrine tumors metastatic to the liver. The findings, presented at the ASCO 2021 Annual Meeting, showed an 83% disease control rate (DCR), with a median progression-free survival (PFS) of 9.2 months and median overall survival (OS) of 22.5 months. Among the 12 heavily pre-treated patients, 42% achieved a partial response. The trial indicated a strong immune response, with mild side effects and no major safety concerns reported.
Provectus (OTCQB: PVCT) announced a $2.5 million funding commitment from the State of Tennessee to develop animal health drug products in collaboration with local universities. The initiative will focus on oncology, hematology, and dermatology treatments for animals, utilizing Provectus' halogenated xanthene platform. Key milestones include prior studies in solid tumors in companion animals and human clinical trials. Board members express gratitude towards the state for supporting innovation and aim to address local health needs through this partnership.
Provectus (OTCQB: PVCT) announced the acceptance of two abstracts for the ASCO 2021 Annual Meeting, showcasing the potential of PV-10, an investigational cancer immunotherapy. The first abstract details a Phase I clinical trial focused on intralesional PV-10 administration for metastatic neuroendocrine tumors, conducted at The Queen Elizabeth Hospital in Australia. The second abstract presents preclinical research on the oral administration of PV-10 for treating high-risk adult solid tumors. Both presentations highlight the ongoing research and potential applications of PV-10 in cancer therapy.
Provectus (OTCQB: PVCT) announced a published study on PV-10, showing a 46% complete response rate and 86% overall response rate in treating in-transit melanoma lesions in 48 patients. Conducted at the Melanoma Institute Australia, the study highlights a median age of 75.1 years for participants and significant overall survival rates of 77% and 56% at 12 and 24 months, respectively. This publication marks the fifth study of PV-10, emphasizing its potential as a low-toxicity treatment option for patients with limited alternatives.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/678,133, covering the use of intralesional PV-10 in combination with immune checkpoint inhibitors for adult solid tumor cancers. This includes melanoma, breast, liver, prostate, and lung cancers. The allowed patent is the fourth continuation of a foundational cancer treatment patent granted in 2015. Vice Chair Dominic Rodrigues highlighted that this new patent strengthens their oncology drug development program, focusing on the combination therapies that enhance immune response against solid tumors.